4
K. Kim et al. / Tetrahedron xxx (2015) 1e5
2H), 3.77 (s, 2H), 2.89 (s, 3H) ppm; minor rotamer:
d 7.35e7.20 (m,
9H), 7.08 (s, 1H), 4.51 (s, 2H), 3.74 (s, 2H), 2.94 (s, 3H) ppm.
4.2.10. 1-(Phenylacetyl)piperidine (3ja).7d Yellow oil (76.0 mg, 75%).
1H NMR (400 MHz, CDCl3)
d 7.25e7.21 (m, 2H), 7.18e7.14 (m, 3H),
3.65 (s, 2H), 3.49 (t, J¼5.4 Hz, 2H), 3.28 (t, J¼5.4 Hz, 2H), 1.52e1.40
(m, 4H), 1.29e1.23 (m, 2H) ppm.
4.2.11. N-(3-Phenylpropyl)benzamide (3ab).24 White solid (98.0 mg,
82%). 1H NMR (500 MHz, CDCl3)
d 7.68e7.66 (m, 2H), 7.49e7.48 (m,
Scheme 2. Proposed mechanism for dehydrogenative amidation via a direct pathway
or via a base-catalyzed transamidation pathway through esters.
1H), 7.42e7.38 (m, 2H), 7.31e7.30 (m, 2H), 7.24e7.20 (m, 3H), 6.05
(br s, 1H), 3.53 (q, J¼6.60 Hz, 2H), 2.75 (t, J¼7.59 Hz, 2H), 2.02e1.96
(m, 2H) ppm.
4.2.1. 2-Phenyl-N-(3-phenylpropyl)acetamide (3aa).21 White solid
(113.4 mg, 90%). 1H NMR (500 MHz, CDCl3)
d 7.39e7.36 (m, 2H),
4.2.12. N-(3-Phenylpropyl)pentanamide
(100.4 mg, 92%). 1H NMR (500 MHz, CDCl3)
(3ac).13a Brown
oil
7.33e7.30 (m, 1H), 7.28e7.24 (m, 4H), 7.20e7.17 (m, 1H), 7.10 (d,
J¼7.25 Hz, 2H), 5.32 (br s, 1H), 3.56 (s, 2H), 3.25 (q, J¼6.71 Hz, 2H),
2.56 (t, J¼7.68 Hz, 2H), 1.80e1.74 (m, 2H) ppm.
d
7.31e7.28 (m, 2H),
7.22e7.18 (m, 3H), 5.44 (br s, 1H), 3.31 (q, J¼6.65 Hz, 2H), 2.66 (t,
J¼7.65 Hz, 2H), 2.14 (t, J¼7.64 Hz, 2H), 1.88e1.82 (m, 2H), 1.62e1.56
(m, 2H), 1.38e1.31 (m, 2H), 0.96e0.88 (m, 3H) ppm.
4.2.2. N-Hexyl-2-phenylacetamide (3ba).7a White solid (89.3 mg,
81%). 1H NMR (400 MHz, CDCl3)
d 7.33e7.21 (m, 5H), 5.61 (br s, 1H),
4. 2.13 . N-( 3-P henyl pro pyl )cycl opropa nec ar boxa mid e
(3ad).25 White solid (68.4 mg, 67%). 1H NMR (400 MHz, CDCl3)
3.52 (s, 2H), 3.15 (q, J¼6.70 Hz, 2H), 1.39e1.35 (m, 2H), 1.23e1.19 (m,
6H), 0.82 (t, J¼6.90 Hz, 3H) ppm.
d
7.28e7.24 (m, 2H), 7.18e7.15 (m, 3H), 5.85 (br s, 1H), 3.28 (q,
J¼6.63 Hz, 2H), 2.63 (t, J¼7.68 Hz, 2H), 1.86e1.78 (m, 2H), 1.31e1.25
4.2.3. N-Benzyl-2-phenylacetamide (3ca).21 White solid (95.9 mg,
(m, 1H), 0.94e0.91 (m, 2H), 0.70e0.66 (m, 2H) ppm.
85%). 1H NMR (500 MHz, CDCl3)
d 7.38e7.35 (m, 2H), 7.32e7.24 (m,
(3ae).26 White
7.64 (d,
6H), 7.19 (d, J¼7.22 Hz, 2H), 5.68 (br s, 1H), 4.43 (d, J¼5.80 Hz, 2H),
4.2.14. 4-Methoxy-N-(3-phenylpropyl)benzamide
solid (100.2 mg, 74%). 1H NMR (500 MHz, CDCl3)
3.65 (s, 2H) ppm.
d
J¼8.82 Hz, 2H), 7.32e7.29 (m, 2H), 7.24e7.20 (m, 3H), 6.91 (d,
J¼8.82 Hz, 2H), 5.97 (br s, 1H), 3.85 (s, 3H), 3.51 (q, J¼6.60 Hz, 2H),
2.74 (t, J¼7.59 Hz, 2H), 2.01e1.95 (m, 2H) ppm.
4.2.4. N-(4-Methoxybenzyl)-2-phenylacetamide
(3da).22 White
d 7.38e7.35 (m,
solid (128.8 mg, >97%). 1H NMR (500 MHz, CDCl3)
2H), 7.31e7.26 (m, 3H), 7.12 (d, J¼8.52 Hz, 2H), 6.85e6.82 (m, 2H),
5.61 (br s, 1H), 4.36 (d, J¼5.80 Hz, 2H), 3.79 (s, 3H), 3.63 (s,
2H) ppm.
4.2.15. 4-Fluoro-N-(3-phenylpropyl)benzamide (3af).13a Colorless
oil (88.9 mg, 69%). 1H NMR (400 MHz, CDCl3)
d 7.65e7.62 (m, 2H),
7.31e7.25 (m, 2H), 7.20e7.16 (m, 3H), 7.04e6.98 (m, 2H), 6.32 (br s,
1H), 3.44 (q, J¼6.67, 2H), 2.68 (t, J¼7.44 Hz, 2H), 1.96e1.89 (m,
2H) ppm.
4.2.5. N-(2-Methylbenzyl)-2-phenylacetamide (3ea). Yellow solid
(98.1 mg, 82%). 1H NMR (400 MHz, CDCl3)
d 7.35e7.31 (m, 2H),
7.29e7.25 (m, 3H), 7.19e7.08 (m, 4H), 5.82 (br s, 1H), 4.38 (d,
J¼5.52 Hz, 2H), 3.58 (s, 2H), 2.22 (s, 3H) ppm. 13C NMR (100 MHz,
4.2.16. N-(3-Phenylpropyl)-2-furancarboxamide (3ag).13a Yellow oil
(74.4 mg, 65%). 1H NMR (500 MHz, CDCl3)
d
7.39 (t, J¼0.86 Hz, 1H),
CDCl3)
d 170.76, 136.25, 135.67, 130.44, 129.36, 128.98, 128.00,
127.61, 127.33, 126.10, 43.69, 41.79 ppm; HRMS (ESI) calcd for
7.28e7.25 (m, 2H), 7.18 (d, J¼7.20 Hz, 3H), 7.07 (d, J¼3.58 Hz, 1H),
6.47e6.45 (m, 1H), 6.38 (br s, 1H), 3.44 (q, J¼6.68 Hz, 2H), 2.69 (t,
J¼7.64 Hz, 2H), 1.96e1.88 (m, 2H).
C
16H17NONa: 262.1202, found: 262.1202 [MNaþ].
4.2.6. N-(4-Chlorobenzyl)-2-phenylacetamide (3fa).13a White solid
(54.0 mg, 42%). 1H NMR (500 MHz, CDCl3)
7.38e7.35 (m, 2H),
d
Acknowledgements
7.32e7.26 (m, 5H), 7.12 (d, J¼8.27 Hz, 2H), 5.67 (br s, 1H), 4.39 (d,
J¼5.95 Hz, 2H), 3.64 (s, 2H) ppm.
This research was supported by the National Research Founda-
tion
of
Korea
(NRF-2014R1A2A1A11050028;
Korea CCS R&D Center;
NRF-
NRF-
4.2.7. 2-Phenyl-N-(4-(trifluoromethyl)benzyl)acetamide
(3ga). -
7.56 (d,
White solid (62.6 mg, 43%). 1H NMR (500 MHz, CDCl3)
d
2014M1A8A1049347,
2014R1A5A1011165, Center for New Directions in Organic Synthe-
sis), funded by the Korean Government.
J¼8.18 Hz, 2H), 7.40e7.37 (m, 2H), 7.33e7.32 (m, 1H), 7.30e7.27 (m,
4H), 5.76 (br s, 1H), 4.48 (d, J¼5.99 Hz, 2H), 3.67 (s, 2H) ppm. 13
C
NMR (75 MHz, CDCl3)
d 171.22, 142.41, 134.71, 129.38, 129.08,
127.56, 127.48, 129.89, 125.53 (q, J¼11.36 Hz), 122.28, 43.66, 42.96.
19F NMR (376 MHz, CDCl3)
ꢁ62.59 ppm; HRMS(ESI) calcd for
16H14F3NONa: 316.0920, found: 316.0920 [MNaþ].
Supplementary data
d
C
Supplementary data associated with this article can be found in
4.2.8. 2-Phenyl-N-(pyridin-3-ylmethyl)acetamide (3ha).23 Yellow
solid (79.1 mg, 70%). 1H NMR (500 MHz, CDCl3)
8.52e8.50 (m, 2H),
d
References and notes
7.65 (d, J¼7.53 Hz, 1H), 7.39e7.36 (m, 2H), 7.32e7.27 (m, 4H), 5.88
(br s, 1H), 4.46 (d, J¼6.13 Hz, 2H), 3.66 (s, 2H) ppm.
4.2.9. N-Benzyl-N-methyl-2-phenylacetamide (3ia).8b Yellow oil
(85.0 mg, 71%). 1H NMR (400 MHz, CDCl3) 1:1.35 mixture of
rotamers; major rotamer:
d 7.35e7.20 (m, 9H), 7.09 (s, 1H), 4.60 (s,